Your Next Customer Isn’t Googling You. They’re Asking AI 
Rhino Propels Federated AI into the Enterprise Tech Stack GoMeyra Celebrates Two Year Anniversary
Pandemic-born provider of innovative, real-time software for the healthcare industry celebrates milestones, achievements and new…
University of Phoenix Vice Provost Doris Savron to Speak at PESC Data Summit
Education leaders will meet to discuss emerging initiatives and data standards PHOENIX–(BUSINESS WIRE)–University of Phoenix…
Arcserve Independent Global Study Finds Remote Working Creating Data Vulnerability Gap
Data explosion of remote working leaves fragmented data requiring protection Majority of companies have no…
Celo Ecosystem Projects Raise Over $77 Million in Funding to Support Financial Inclusion, Interoperability, Regenerative Finance (ReFi), and More
Companies like impactMarket, Loam, Tatum, and Hyperlane secure new venture milestones for mainstream adoption of…
Aquestive Therapeutics Licenses Sympazan® (clobazam) Oral Film to Assertio Holdings, Inc.
WARREN, N.J., Oct. 27, 2022 (GLOBE NEWSWIRE) — Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical…
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
JUPITER, Fla., Oct. 27, 2022 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”,…
Homology Medicines Presents on Design of pheEDIT Trial Evaluating One-Time Nuclease-Free Gene Editing Candidate HMI-103 for PKU at American Society of Human Genetics Meeting
– Additional Presentation Focused on Use of Single-Molecule, Modified Base Sequencing to Support Vector Design…
Biora Therapeutics Announces Sale of Cell-Free DNA Patent Rights
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech…
Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc.
Trailing 12 Month Revenues of Sympazan Were $9.5 MillionAssertio Paid $9.0 Million Upfront, Additional $6.0…
Ventyx Biosciences to Participate in Three Upcoming Investor Conferences
ENCINITAS, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Ventyx Biosciences, Inc. (Nasdaq: VTYX), (“Ventyx”), a…
Aphaia Pharma Announces Enrollment of First Patient in Phase 2 Study of APH-012 for Chronic Weight Management in Individuals with Obesity
ZUG, Switzerland, Oct. 27, 2022 (GLOBE NEWSWIRE) — Aphaia Pharma, a clinical-stage biopharmaceutical company harnessing…
Software Effective Solutions Subsidiary MEDCANA (OTC: SFJW) Announces Successful Launch of Test Greenhouses for Microclimates and Genetics with Colombia Partner Firms
MedCana’s initial focus is on partnering and developing companies in Latin America with an initial…
Salarius Pharmaceuticals Presents Favorable Preclinical Data on SP-3164 at the 5th Annual Targeted Protein Degradation Conference
Data showcased novel compound with potential for improved anti-cancer activity over other molecular glues Salarius…
CRISPR Therapeutics Announces Planned Transition of Chief Operating Officer
ZUG, Switzerland and BOSTON, Oct. 27, 2022 (GLOBE NEWSWIRE) — CRISPR Therapeutics (Nasdaq: CRSP), a…
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage…
Rain Therapeutics to Report Third Quarter 2022 Financial Results and Highlights of Recent Progress on November 10, 2022
NEWARK, Calif., Oct. 27, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a…
Selecta Biosciences to Host Conference Call and Webcast to Discuss Third Quarter 2022 Financial Results and Provide Business Update
WATERTOWN, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology…
Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical…
Mustang Bio Announces Phase 1/2 Clinical Trial Data of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, to be Presented at 11th International Workshop for Waldenstrom’s Macroglobulinemia
MB-106 demonstrated 100% overall response rate in Waldenstrom macroglobulinemia Data to be presented by Fred…
Jounce Therapeutics to Announce Third Quarter 2022 Financial Results and Host Conference Call on Thursday, November 10, 2022
CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) — Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage…